Study S001209

A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07078838
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 40
Start: 2027-01
Primary completion: 2029-03
Lead sponsor: UNC Lineberger Comprehensive Cancer Center
Conditions: Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Secondary identifiers: NIH:U01CA281026

Registered primary outcomes

Anti-proliferative effect of Tirzepatide [At 4th week (during surgery)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.